VNDA - Vanda Pharmaceuticals Acquires Rights To Multiple Sclerosis Drug From Johnson & Johnson's Company | Benzinga
Vanda Pharmaceuticals Inc (NASDAQ: VNDA) has acquired U.S. and Canadian rights to Ponvory (ponesimod) from Actelion Pharmaceuticals Ltd, a Johnson & Johnson company (NYSE: JNJ).
The FDA and Health Canada approved Ponvory to treat adults with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease.
Vanda paid $100 million to acquire the U.S. and Canadian rights ...